What Acadia Pharmaceuticals Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 5 | 24 |
| Total trades | 8 | 51 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 52,413 | 245,425 |
| Disposed | 36,699 | 141,641 |
| Net activity | +15,714 | +103,784 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Aug 06 | Open-market sale · S | −9,292 | $29.34 | −$273K | 67,828 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Aug 06 | Open-market sale · S | −5,000 | $29.00 | −$145K | 77,120 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Aug 06 | Exercise / conversion · M | +14,292 | $17.84 | +$255K | 82,120 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Aug 05 | Open-market sale · S | −5,849 | $29.00 | −$170K | 67,828 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Aug 05 | Exercise / conversion · M | +5,849 | $17.84 | +$104K | 73,677 |
| Thompson Elizabeth H.z. | EVP, Head of Research & Dev | Jul 30 | Disclosed 10b5-1 sale · S | −50 | $26.17 | −$1.31K | 18,994 |
| Thompson Elizabeth H.z. | EVP, Head of Research & Dev | Jul 30 | Disclosed 10b5-1 sale · S | −16,508 | $26.13 | −$431K | 19,044 |
| Thompson Elizabeth H.z. | EVP, Head of Research & Dev | Jul 29 | Exercise / conversion · M | +32,272 | — | — | 35,552 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Jun 26 | Open-market sale · S | −11,421 | $26.08 | −$298K | 13,088 |
| Daly James M | Director | May 29 | Exercise / conversion · M | +8,107 | — | — | 12,148 |
| Harrigan Edmund | Director | May 29 | Exercise / conversion · M | +8,107 | — | — | 43,148 |
| Baker Bros. Advisors Lp | Director | May 29 | Grant / award · A | +18,622 | — | — | 39,384,587 |
| Baker Bros. Advisors Lp | Director | May 29 | Grant / award · A | +18,622 | — | — | 3,677,357 |
| Brege Laura | Director | May 29 | Exercise / conversion · M | +8,107 | — | — | 23,202 |
| Poole Jonathan | Director | May 29 | Exercise / conversion · M | +2,010 | — | — | 2,010 |
| Garofalo Elizabeth A. | Director | May 29 | Exercise / conversion · M | +8,107 | — | — | 33,489 |
| Ndu Adora | Director | May 29 | Exercise / conversion · M | +8,107 | — | — | 32,908 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | May 26 | Open-market sale · S | −5,401 | $21.18 | −$114K | 24,509 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | May 04 | Disclosed 10b5-1 sale · S | −1,332 | $21.79 | −$29K | 29,129 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | May 04 | Disclosed 10b5-1 sale · S | −3,506 | $21.79 | −$76.4K | 66,145 |
Loading...
